![Colin Macaulay](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Colin Macaulay
Fondateur chez Viron Therapeutics, Inc.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
James Moodie Rae | M | - |
Viron Therapeutics, Inc.
![]() Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | 17 ans |
Robert Browne | M | - |
Viron Therapeutics, Inc.
![]() Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Bill James Peck | M | 64 |
University of Alberta
| - |
Grant McFadden | M | - |
Viron Therapeutics, Inc.
![]() Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | 19 ans |
Ronald Kisic | M | - |
University of Alberta
| 8 ans |
R. Allford | M | - |
University of Alberta
| 8 ans |
Neil Warma | M | 61 |
Viron Therapeutics, Inc.
![]() Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | 3 ans |
Bruce Beynon | M | 60 |
University of Alberta
| 6 ans |
Christian Bayle | M | 55 |
University of Alberta
| 5 ans |
Miles W. Safranovich | M | - |
University of Alberta
| 9 ans |
Raymond Bower | M | - |
University of Alberta
| 4 ans |
Kevin V. Sullivan | M | 49 |
Viron Therapeutics, Inc.
![]() Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | 10 ans |
Dale Hildebrand | M | 60 |
University of Alberta
| 7 ans |
Kris Smith | M | - |
University of Alberta
| 4 ans |
Terry Caelli | M | - |
University of Alberta
| 7 ans |
Kam Lun Eric Ng | M | 63 |
University of Alberta
| 4 ans |
Cameron R. Fink | M | 55 |
University of Alberta
| 4 ans |
John Williams | M | 72 |
University of Alberta
| 4 ans |
Tammy DuPerron | F | 63 |
University of Alberta
| 4 ans |
David Anderson | M | 54 |
University of Alberta
| 4 ans |
Steven James Glover | M | - |
University of Alberta
| 2 ans |
Keung Jimmy Chik Wong | M | - |
University of Alberta
| 4 ans |
Paul Kristensen | M | - |
University of Alberta
| 4 ans |
John Bossio | M | 55 |
University of Alberta
| 4 ans |
Da Li Zhang | M | 64 |
University of Alberta
| 1 ans |
Kar Loon Quek | M | 61 |
University of Alberta
| 4 ans |
Jeffrey Green | M | - |
University of Alberta
| 4 ans |
Ben Nyland | M | 54 |
University of Alberta
| 4 ans |
Darrell Cotterill | M | - |
University of Alberta
| 4 ans |
Bruno Kasper | M | - |
University of Alberta
| 4 ans |
Tom Peterson | M | - |
University of Alberta
| 4 ans |
Bruce N. Moisey | M | 62 |
University of Alberta
| 4 ans |
Scott Carter | M | - |
University of Alberta
| 4 ans |
Dwayne William Sorobey | M | 59 |
University of Alberta
| 4 ans |
Lisa Doig | F | - |
University of Alberta
| 4 ans |
Stephanie Sterling | F | 57 |
University of Alberta
| 4 ans |
Conan Taylor | M | - |
University of Alberta
| 4 ans |
Russell Edward Wlad | M | - |
University of Alberta
| 4 ans |
Martin Vydra | M | - |
University of Alberta
| 3 ans |
Richard Roy | M | - |
University of Alberta
| 4 ans |
Michael Power | M | - |
University of Alberta
| 4 ans |
Kwok Hay Wong | M | 75 |
University of Alberta
| 3 ans |
Jugdutt Singh | M | - |
University of Alberta
| 1 ans |
Troy G. Tews | M | - |
University of Alberta
| 4 ans |
Steve Dobler | M | 60 |
University of Alberta
| 4 ans |
Bryce Kremnica | M | - |
University of Alberta
| 4 ans |
Doyle Sam | M | - |
University of Alberta
| 4 ans |
Louis Picco | M | 58 |
University of Alberta
| 4 ans |
Louis Hugo Francescutti | M | - |
University of Alberta
| 3 ans |
Michèle Stanners | F | 66 |
University of Alberta
| 3 ans |
Arokia Nathan | M | - |
University of Alberta
| 3 ans |
Wendy Henkelman | F | 59 |
University of Alberta
| 4 ans |
Doug McMillan | M | - |
University of Alberta
| 4 ans |
Gregory F. Juneau | M | 57 |
University of Alberta
| 4 ans |
Dean Schultz | M | - |
University of Alberta
| 4 ans |
Antoinette Boquiren | F | 56 |
University of Alberta
| 4 ans |
Michael J. Rusch | M | 78 |
University of Alberta
| 4 ans |
Tony Bright | M | - |
University of Alberta
| 4 ans |
John Williamson | M | 64 |
University of Alberta
| 4 ans |
Terry Tucker | M | - |
University of Alberta
| 4 ans |
Philip Collins | M | - |
University of Alberta
| 4 ans |
Shane Ebert | M | - |
University of Alberta
| 4 ans |
Robert James Maddigan | M | - |
University of Alberta
| 4 ans |
Stuart Olley | M | - |
University of Alberta
| 2 ans |
Norm A. Gretzinger | M | - |
University of Alberta
| 4 ans |
Kerry Kozlowski | F | - |
University of Alberta
| 4 ans |
Douglas Bartole | M | 56 |
University of Alberta
| 4 ans |
Wendell Zerb | M | 60 |
University of Alberta
| 4 ans |
Don Rawson | M | - |
University of Alberta
| 4 ans |
Allan Gregory Stepa | M | - |
University of Alberta
| 4 ans |
Patrick Stiles | M | - |
University of Alberta
| 4 ans |
Mark G. Maybank | M | 53 |
University of Alberta
| 5 ans |
Bruce Daniel Beingessner | M | 59 |
University of Alberta
| 4 ans |
Robert Foster | M | 65 |
University of Alberta
| 9 ans |
Garey James Aitken | M | - |
University of Alberta
| 4 ans |
Changxin Li | M | 63 |
University of Alberta
| 3 ans |
Sean W. Duffee | M | - |
University of Alberta
| 4 ans |
Gordon Robert McCormack | M | 59 |
University of Alberta
| 4 ans |
Thorsten Brost | M | - |
University of Alberta
| 4 ans |
Michael R. Smillie | M | - |
University of Alberta
| 4 ans |
Cheryle Donahue | F | - |
University of Alberta
| 4 ans |
John Haylock | M | - |
University of Alberta
| 4 ans |
Gregory Francis Kennedy | M | 74 |
University of Alberta
| 4 ans |
Cary Pothorin | M | - |
University of Alberta
| 4 ans |
Ross McElroy | M | 60 |
University of Alberta
| 4 ans |
Monroe Thomas | M | - |
University of Alberta
| 4 ans |
Darin Labrenz | M | 58 |
University of Alberta
| 4 ans |
Mark Krantz | M | - |
University of Alberta
| 4 ans |
Darren Gee | M | 56 |
University of Alberta
| 4 ans |
Gregory J. Hansen | M | 58 |
University of Alberta
| 4 ans |
Craig Hruska | M | - |
University of Alberta
| 4 ans |
Jeffrey G. Sheremeta | M | 52 |
University of Alberta
| 4 ans |
Sean M. Brett | M | 58 |
University of Alberta
| 5 ans |
Donald Boykiw | M | - |
University of Alberta
| 3 ans |
Kevin J. Inman | M | - |
University of Alberta
| 4 ans |
Shaun E. Alspach | M | - |
University of Alberta
| 4 ans |
Arie B. Prins | M | - |
University of Alberta
| 4 ans |
George Chow | M | 62 |
University of Alberta
| 3 ans |
Darin R. Coutu | M | 58 |
University of Alberta
| 4 ans |
Leanne Geale | F | 59 |
University of Alberta
| 4 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Canada | 100 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Colin Macaulay
- Réseau Personnel